The short version
- The Centers for Disease Control and Prevention has declined to validate a high-throughput measles testing method requested by Western state health departments.
- Officials argue that current low-volume diagnostic methods are insufficient for managing large-scale outbreaks or scaling up response efforts quickly.
- The agency stated it is prioritizing emerging technologies, though it did not specify plans for validating existing high-capacity assays developed by state labs.
The Centers for Disease Control and Prevention has formally denied a request from public health leaders in four Western states to validate a rapid, high-volume testing protocol for measles. The decision, communicated in May, leaves regional laboratories without federal endorsement for diagnostic tools capable of processing large batches of samples simultaneously. Health officials in California, Washington, Oregon, and Hawaii have since issued a joint letter urging CDC Director Erica Schwartz to reconsider the stance, warning that the lack of standardized high-throughput capacity could severely hamper outbreak response efforts.
The core of the dispute centers on laboratory efficiency during potential surges in cases. Currently, public health laboratories rely on individual polymerase chain reaction tests, which process samples one by one or in small groups. This method is time-consuming and resource-intensive when faced with a sudden influx of suspected measles cases. In contrast, high-throughput platforms, such as the Hologic Panther Fusion system widely adopted during the coronavirus pandemic, can analyze up to 500 tests within eight hours. The absence of a CDC-validated protocol for running measles diagnostics on these machines means labs cannot easily switch to mass testing if an outbreak escalates.
State laboratories have already developed solutions that remain unused at the federal level. During a significant measles outbreak in West Texas last year, state scientists created a high-volume test designed for rapid processing. Similarly, ARUP Laboratories has developed its own assay. According to the letter from the West Coast Health Alliance, the CDC has reportedly completed studies on both the Texas and ARUP tests. However, officials note that these evaluations did not constitute full validations or comprehensive comparisons required for widespread adoption. Without official publication of a protocol, other public health labs cannot legally or technically implement these methods.
The federal agency’s justification for the denial focuses on strategic resource allocation. Emily Hilliard, a spokesperson for the U.S. Department of Health and Human Services, stated that the CDC is prioritizing emerging technologies to address the current measles situation. The department emphasized its commitment to supporting state and local health departments in strengthening detection and response capabilities. However, the spokesperson did not provide specific details regarding whether the CDC has concrete plans to validate a high-throughput measles assay in the near future, leaving questions about the timeline for improved diagnostic infrastructure.
Health officials argue that preparedness requires having validated tools ready before crises occur. The West Coast Health Alliance contends that if a large outbreak were to hit their region, the inability to scale up diagnostic testing quickly would impair both patient care and public health investigations. They note that the same high-throughput capacity needed for measles could also strengthen responses to other known pathogens like Ebola or hantavirus, as well as emerging threats. The alliance views the validation of a Panther Fusion assay as an essential component of modern epidemic readiness.
The delay in adopting these technologies highlights a gap between state-level innovation and federal standardization. While Texas laboratories successfully deployed their test during last year’s outbreak, they have not distributed or published the protocol for broader use. The CDC holds the authority to implement and publish such protocols, enabling labs across the country to run standardized diagnostic tests. Until this occurs, regional health departments must rely on slower, lower-volume methods that may struggle to keep pace with rapid disease transmission.
The letter from Western health officials also calls for the creation of protocols to test for other high-priority pathogens. This broader request underscores a systemic concern about the flexibility of public health laboratories in the face of diverse biological threats. By focusing on emerging technologies rather than validating existing, proven methods, the CDC may be leaving critical gaps in immediate response capabilities. The alliance stresses that having tests ready to go is not just beneficial but necessary for effective outbreak management.
As measles cases continue to draw attention, the debate over diagnostic capacity remains unresolved. The denial of the validation request has prompted a formal appeal from multiple state health departments, signaling growing frustration with federal priorities. Whether the CDC will reverse its decision or develop new guidelines remains uncertain. In the meantime, laboratories in California, Hawaii, Oregon, and Washington continue to operate without access to high-throughput measles testing, relying on older methods that may prove inadequate during a major surge.
The situation illustrates the tension between investing in future technological advancements and maintaining robust current infrastructure. While emerging technologies hold promise for long-term public health security, immediate threats require reliable, scalable solutions today. The lack of a validated high-volume test means that if another significant outbreak occurs, response times could be delayed, potentially allowing the virus to spread further before containment measures can be fully implemented.
Public health experts continue to monitor the CDC’s actions closely. The outcome of this appeal could set a precedent for how federal agencies handle requests for diagnostic validation from state partners. If the agency maintains its current stance, it may face increased pressure to justify its prioritization strategies. Conversely, a reversal could lead to faster adoption of efficient testing methods nationwide, improving readiness for both measles and other infectious diseases.
Sources behind this briefing
Go to the original reporting
- The Guardian World↗CDC denies approval for high volume measles test, ‘prioritizing emerging technologies’
